Bexxar Solution For Injection 35-225Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Bexxar: Solution for injection (35-225mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

TOSITUMOMAB (TOE sih too MOE mab) is a chemotherapy drug. This medicine allows radiation to target specific kinds of white blood cells. It is used to treat non-Hodgkin's lymphoma.

In-Depth Information
Select a Medication

Bexxar Therapeutic Packaging Tositumomab 14mg/ml Solution for Injection

NDC: 000073260
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Non-Hodgkin's Lymphoma (NHL)

Sometimes used for but not FDA approved for the following conditions:
Stem Cell Transplant Preparation

Storage Information
Store unreconstituted product in refrigerator (36 to 46 degrees F)
Reconstituted product should be refrigerated and used within 24 hours if not used immediately
Protect from light
Reconstituted product is stable for up to 8 hours at room temperature (77 degrees F)
Discard unused portion. Do not store for later use.
Protect from freezing
Store reconstituted product in refrigerator (36 to 46 degrees F)
Bexxar Therapeutic Packaging Tositumomab 14mg/ml Solution for Injection

Reported Side Effects for Bexxar Therapeutic Packaging Tositumomab 14mg/ml Solution for Injection

Infection Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Paresis Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Muscle Pain Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Excessive Sweating Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Skin Rash Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Upset Stomach Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Joint Pain Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Weight Loss Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Back Pain Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Low Blood Pressure Incidence:
1.0%*
Severity: SEVERE
Onset: RAPID
Chills Incidence:
1.0%*
Severity: SEVERE
Onset: RAPID
Cough Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Constipation Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Vomiting Incidence:
1.0%*
Severity: SEVERE
Onset: EARLY
Fever Incidence:
2.0%*
Severity: SEVERE
Onset: EARLY
Weakness Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Secondary Malignancy Incidence:
3.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Stomach Pain Incidence:
3.0%*
Severity: SEVERE
Onset: EARLY
Shortness Of Breath Incidence:
3.0%*
Severity: SEVERE
Onset: EARLY
Upset Stomach Incidence:
3.0%*
Severity: SEVERE
Onset: EARLY
Lightheadedness Incidence:
5.0%*
Severity: MILD
Onset: EARLY
Peripheral Vasodilation Incidence:
5.0%*
Severity: MODERATE
Onset: RAPID
Drowsiness Incidence:
5.0%*
Severity: MILD
Onset: EARLY
Underactive Thyroid Incidence:
7.0%*
Severity: MODERATE
Onset: DELAYED
Chest Pain Incidence:
7.0%*
Severity: MODERATE
Onset: EARLY
Fluid Retention Incidence:
9.0%*
Severity: MODERATE
Onset: DELAYED
Itching Incidence:
10.0%*
Severity: MILD
Onset: RAPID
Antibody Formation Incidence:
10.0-70.0%*
Severity: MODERATE
Onset: DELAYED
Rhinitis Incidence:
10.0%*
Severity: MILD
Onset: EARLY
Bleeding Incidence:
12.0%*
Severity: MODERATE
Onset: EARLY
Sore Throat Incidence:
12.0%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
12.0%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
14.0%*
Severity: MILD
Onset: DELAYED
Headache Incidence:
16.0%*
Severity: MILD
Onset: EARLY
Anemia Incidence:
29.0%*
Severity: SEVERE
Onset: DELAYED
Low Platelet Count Incidence:
53.0%*
Severity: SEVERE
Onset: DELAYED
Low White Blood Cells Incidence:
63.0%*
Severity: SEVERE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

SECOND Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

THIRD Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Bexxar

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5